HIMS Stock Forecast & Price Target

Hims & Hers Health is supported by strong weight loss demand, improving retention, and lower cancellations from AI-powered tools, which help lift customer engagement and reduce non-clinical support burden. The company’s 2Q26 results showed revenue of $753.2mm, adjusted EBITDA of $60.3mm, and subscribers rising to 2.891mm, while monthly revenue per average subscriber increased 21% to $92, underscoring healthier monetization. Its outlook is further strengthened by rapid testosterone growth, expected international revenue above $600mm in 2026, and ongoing investment in AI and new categories that could expand long-term operating leverage despite near-term margin pressure.

Hims & Hers Health is facing a fundamentally tougher profit path because strong revenue growth is being purchased with heavier spending on international expansion, branded weight-loss products, AI, and new therapies, which is already showing up as margin pressure and a lower EBITDA outlook. The company’s direct-to-consumer model also depends on durable unit economics, yet rising customer acquisition costs, higher churn, and intense competition from large healthcare firms and venture-backed entrants could weaken marketing yields and compress margins. Regulatory risk is another major overhang: tighter rules on compounding, scrutiny in the GLP-1 market, and the need to potentially build insurance infrastructure for branded offerings could raise costs and erode Hims & Hers’ differentiated, cash-pay model.